Market News & Trends
Inceptor Bio Launches Next-Generation CAR-T, CAR-M, & NK/NKT Platform Focused on Advancing Cell & Gene Therapies to Cure Difficult-to-Treat Cancers
Inceptor Bio recently announced it is developing multiple next-generation cell and gene therapy platforms to cure difficult-to-treat cancers. Inceptor Bio will create a portfolio of…
HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator
HiberCell recently announced the initiation of a Phase 1a multicenter, open-label, dose escalation trial of its orally administered HC-5404-FU in patients with selected metastatic solid…
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line & Beyond HNSCC
Cue Biopharma, Inc. recently announced it has dosed the first patient in the Part B expansion phase of its Phase 1 monotherapy clinical trial of…
Cocrystal’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 & Two Prominent SARS-CoV-2 Variants
Cocrystal Pharma, Inc. recently announced its lead preclinical SARS-CoV-2 3CL protease inhibitor CDI-45205 is active against SARS-CoV-2 and two prominent SARS-CoV-2 variants. A third-party laboratory…
Yourway Breaks Ground on Major Expansion, Including Phase 1 Clinical Trials Unit
Yourway recently announced an expansion underway at its headquarters in Allentown, PA. An expanded complex is being constructed for Yourway’s global operation, adding an additional…
Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-Targeting TriTAC HPN424
Harpoon Therapeutics, Inc. recently presented interim data from the ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate…
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of its Adenosine A2A Receptor Antagonist
iTeos Therapeutics, Inc. recently announced new clinical data from its ongoing Phase 1/2a clinical trial of inupadenant (EOS-850), a next-generation adenosine receptor (A2AR) antagonist, at…
IN8bio Completes Treatment of First Cohort in Phase 1 Clinical Trial With Gamma Delta T-Cell Therapy in Patients with Newly Diagnosed Glioblastoma Multiforme
IN8bio, Inc. recently announced an update from the ongoing Phase 1 clinical trial of INB-200, its DeltEx drug resistant immunotherapy (DRI), MGMT-gene modified gamma delta…
Cullinan Oncology Announces Phase 1/2a Interim Data for Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients
Cullinan Oncology, Inc. recently announced additional details pertaining to Cullinan Pearl’s ongoing Phase 1/2a trial of CLN-081 in Non-Small Cell Lung Cancer (NSCLC) patients whose…
Addex Starts Phase 2 Clinical Study of ADX71149 for Epilepsy
Addex Therapeutics recently announced the first patients have been enrolled into a Phase 2 clinical study evaluating JNJ-40411813 (ADX71149) in patients with epilepsy. JNJ-40411813 (ADX71149)…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….